Global Clinical Trials has been awarded a Phase I study in COVID-19 patients by a U.S. sponsor. Proud to have 80% of the projects as repeat business, GCT is currently collaborating with the sponsor on another clinical trial in the U.S.
The Investigational Medicinal Product (IMP) is designed to ease the symptoms and reduce SAR COVID-19 viral load. The study will be performed in 30 patients at 2 sites in the U.S.
GCT is proving full-service support for the trial, including project and site management, medical writing, data management and biostatistics. The team is looking forward to the prompt start of the activities.